Farhad Shahsavar

Farhad Shahsavar

Auto-generated profile, based on publicly available information

Farhad Shahsavar

Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Taiwanese Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
SASoheila Akbari
Soheila Akbari
BKBabak Khodadadi
Babak Khodadadi
SASeyyed Amir Yasin Ahmadi
Seyyed Amir Yasin Ahmadi
SASaber Abbaszadeh
Saber Abbaszadeh
FSFarhad Shahsavar
Farhad Shahsavar
Because of the immune modulatory effects of vitamin D3 in preeclampsia, we intend to have a systematic review and meta-analysis on association of both 25-hydroxy vitamin D (25-OHD) level (parametric approach) and 25-OHD deficiency (non-parametric approach) with preeclampsia. As well, for the parametric part, we used receiver operating characteristic (ROC) curve model. We used Web of Science, PubMed and Science Direct data bases through searching in titles. Google Scholar search engine was used in order to find missing papers. Finally 23 studies were imported. Both random and fixed models were reported. Based on the forest plot, lower levels of 25-OHD were significantly associated with risk of preeclampsia (fixed and random P < 0.001). Based on the forest plot, vitamin D deficiency (25-OHD < 20 ng/ml) was significantly associated with risk of preeclampsia (fixed P < 0.0001; random P = 0.0029; fixed OR = 1.33; random OR = 1.54). Based on ROC curve results, we found 2 cutoffs of 10.60 and 20.05 ng/ml. Women with vitamin D deficiency at cutoff 20 ng/ml are more at risk of preeclampsia. This association can be specific up to 90% at 10.60 ng/ml cutoff. Treatment of vitamin D deficiency is necessary before pregnancy.

19 May 2010 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
PDF file
NTN. Tajik
N. Tajik
FSF. Shahsavar
F. Shahsavar
MNM. Nasiri
M. Nasiri
MRM. F. Radjabzadeh
M. F. Radjabzadeh

9 June 2009 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
NTN. Tajik
N. Tajik
FSF. Shahsavar
F. Shahsavar
TMT. Mousavi
T. Mousavi
MRM. F. Radjabzadeh
M. F. Radjabzadeh

29 July 2011 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
PDF file
NTN. Tajik
N. Tajik
FSF. Shahsavar
F. Shahsavar
HPH. Poormoghim
H. Poormoghim
MRM. F. Radjabzadeh
M. F. Radjabzadeh
TMT. Mousavi
T. Mousavi
AJA. Jalali
A. Jalali

10 November 2016 in Genomics Data
Verified
Journal Article
Open access
FSFarhad Shahsavar
Farhad Shahsavar
AVAli-Mohammad Varzi
Ali-Mohammad Varzi
SASeyyed Amir Yasin Ahmadi
Seyyed Amir Yasin Ahmadi
Anthropological studies based on the highly polymorphic gene, human leukocyte antigen (HLA), provide useful information for bone marrow donor registry, forensic medicine, disease association studies, as well as infertility treatment, designing peptide vaccines against tumors, and infectious or autoimmune diseases. The aim of this study was to determine HLA-A and HLA-B allele frequencies in 100 unrelated Lak/lᴂk/individuals from Lorestan province of Iran. Finally, we compared the results with that previously described in Iranian population. Commercial HLA-Type kits from BAG (Lich, Germany) company were used for determination of the HLA-A and HLA-B allele frequencies in genomic DNA, based on polymerase chain reaction with sequence specific primer (PCR-SSP) assay. The differences between the populations in distribution of HLA-A and HLA-B alleles were estimated by chi-squared test with Yate's correction. The most frequent HLA-A alleles were *24 (20%), *02 (18%), *03 (12%) and *11 (10%), and the most frequent HLA-B alleles were *35 (24%), *51 (16%), *18 (6%) and *38 (6%) in Lak population. HLA-A*66 (1%), *74(1%) and HLA-B*48 (1%), *55(1%) were the least observed frequencies in Lak population. Our results based on HLA-A and HLA-B allele frequencies showed that Lak population possesses the previously reported general features of Iranians but still with unique.

10 February 2016 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
FSFarhad Shahsavar
Farhad Shahsavar
MBMahmood Bozorgmehr
Mahmood Bozorgmehr
EMEbrahim Mirzadegan
Ebrahim Mirzadegan
AAAnita Abedi
Anita Abedi
ZLZohreh Mehri Lighvan
Zohreh Mehri Lighvan
AZAmir-Hassan Zarnani
Amir-Hassan Zarnani
Purpose: Cisplatin as a platinum (Pt)-based chemotherapeutic compound is commonly applied for the treatment of several types of cancer. Nonetheless, drug resistance and severe adverse effects have been observed upon using cisplatin. Here, we have explored the cytotoxicity of novel Pt-based compounds on several cancer cell lines. Methods: Five synthetic Pt compounds as well as cisplatin were investigated by XTT assay to determine their cytotoxicity against cell lines originated from prostate, ovary, and breast cancers at different time periods at various concentrations. Additionally, the apoptosis rate in cell lines was determined using flow cytometry. Binding to DNA was investigated through spectrophotometric and viscometric studies. Results: With the exception of one compound, all of the Pt-complexes effectively killed the prostate cancer cell lines (i.e. PC-3 and DU 145). One compound, [Pt(2,2'- dipyridylamine)Cl4].DMF, was chosen as the most potent compound due to its high selective cytotoxic activity and its cytotoxicity was further tested and compared with that of cisplatin on SKOV-3, Caov-4, MDA-MB-231, and MCF7 cell lines. [Pt(2,2'-dipyridylamine)Cl4].DMF had a higher selective cytotoxic capacity in comparison with cisplatin at higher concentrations and longer culture periods. Furthermore, as related to apoptosis induction, treatment with [Pt(2,2'-dipyridylamine)Cl4 ].DMF was significantly more effective than that of cisplatin in five out of six examined cell lines. [Pt(2,2'-dipyridylamine)Cl4].DMF was shown to intercalate into DNA. Conclusions: The current study introduced a novel Pt-based complex with highly selective and potent in vitro anti-tumor impacts superior to those of cisplatin, a conventional chemotherapeutic agent. [Pt (2,2'-dipyridylamine)Cl4].DMF could be regarded as a promising antitumor agent in future investigations.